Literature DB >> 19289333

Dextromethorphan abuse: clinical effects and management.

Frank Romanelli1, Kelly M Smith.   

Abstract

OBJECTIVE: To describe the epidemiology, patient presentation, and clinical management associated with dextromethorphan (DM) abuse. DATA SOURCES: PubMed/Medline search using terms dextromethorphan and abuse through July 2008, bibliographies of selected publications, epidemiology tracking databases. STUDY SELECTION: By the authors. DATA EXTRACTION: English language-published review articles, clinical trials, and case reports that described the epidemiologic and toxicologic profile of DM were included. DATA SYNTHESIS: DM is a relatively inexpensive and easily accessible over-the-counter (OTC) medication intended for use as an antitussive. Increasingly, illicit use of the drug has been reported. At clinical doses, the drug produces few adverse effects. However, when abused in large quantities (>2 mg/kg), the drug has been associated with a dissociative effect similar to those described by ketamine and phencyclidine abusers. Massive ingestions of the drug may be associated with untoward effects, including tachycardia, hypertension, and respiratory depression. Overdose symptoms may also be associated with coformulated products such as antihistamines and sympathomimetic amines. Management is primarily supportive. Naloxone has been used to manage DM toxicity but with conflicting reports of effectiveness.
CONCLUSION: Recent reports indicate that DM is often abused by individuals seeking its dissociative effects. Clinicians should be aware of the abuse potential of DM. Pharmacists might be particularly cognizant of the risks involved with DM abuse as they control OTC access to the drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19289333     DOI: 10.1331/JAPhA.2009.08091

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  8 in total

1.  Adolescents' Misuse of Over-The-Counter Medications: The Need for Pharmacist-led Intervention.

Authors:  Olufunmilola Abraham; Jessica Chmielinski
Journal:  Innov Pharm       Date:  2018-10-15

2.  High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens.

Authors:  Chad J Reissig; Lawrence P Carter; Matthew W Johnson; Miriam Z Mintzer; Margaret A Klinedinst; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2012-04-13       Impact factor: 4.530

3.  Ten Years of Robotripping: Evidence of Tolerance to Dextromethorphan Hydrobromide in a Long-Term User.

Authors:  Travis D Olives; Sean P Boley; Jenna M LeRoy; Samuel J Stellpflug
Journal:  J Med Toxicol       Date:  2019-03-22

4.  Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans.

Authors:  Lawrence P Carter; Chad J Reissig; Matthew W Johnson; Margaret A Klinedinst; Roland R Griffiths; Miriam Z Mintzer
Journal:  Drug Alcohol Depend       Date:  2012-09-16       Impact factor: 4.492

5.  Perioperative Dextromethorphan as an Adjunct for Postoperative Pain: A Meta-analysis of Randomized Controlled Trials.

Authors:  Michael R King; Karim S Ladha; Amanda M Gelineau; T Anthony Anderson
Journal:  Anesthesiology       Date:  2016-03       Impact factor: 7.892

6.  Dextromethorphan withdrawal and dependence syndrome.

Authors:  Jochen Mutschler; Anne Koopmann; Martin Grosshans; Derik Hermann; Karl Mann; Falk Kiefer
Journal:  Dtsch Arztebl Int       Date:  2010-07-30       Impact factor: 5.594

7.  "Robo-tripping": dextromethorphan abuse and its anesthetic implications.

Authors:  Kelly A Linn; Micah T Long; Paul S Pagel
Journal:  Anesth Pain Med       Date:  2014-11-14

Review 8.  Abuse of over-the-counter medicines: a pharmacist's perspective.

Authors:  Sujit S Sansgiry; Archita H Bhansali; Shweta S Bapat; Qingqing Xu
Journal:  Integr Pharm Res Pract       Date:  2016-12-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.